Critical Warnings, Restrictions And Patient Protection (UK First)

Basic Cyclogest Information

• INN (International Nonproprietary Name): Progesterone.
• Brand Names Available In United Kingdom: Utrogestan.
• ATC Code: G03DA04.
• Forms & Dosages: Soft capsules 100 mg and 200 mg; vaginal capsules/softgels 100 mg and 200 mg.
• Manufacturers In United Kingdom: Besins Healthcare and other international suppliers are listed in the product data; specific UK manufacturers not specified.
• Registration Status In United Kingdom: Registered in EU markets under brand names such as Utrogestan; prescription status noted as prescription only (Rx).
• OTC / Rx Classification: Prescription only (Rx).

Patients commonly worry about safety before they start a progesterone product like cyclogest.

Check the absolute contraindications first to keep the person safe.

• Absolute Contraindications:
• Severe hepatic dysfunction.
• Known or suspected breast cancer or other hormone-dependent malignancy.
• Undiagnosed abnormal vaginal bleeding.
• Current or history of thrombosis (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).
• Allergy to peanuts (some capsule excipients may contain peanut oil).
• Pregnancy in certain indications.

Some conditions need careful review rather than an automatic ban.

• Relative Cautions:
• Mild to moderate hepatic or renal impairment — monitor closely.
• Migraine with aura or severe recurrent headaches.
• Asthma where symptoms are unstable.
• Depression or other psychiatric disorders.
• Established cardiovascular disease — assess risk and monitor.

Pre-Treatment Screening Checklist:

• Review history of venous thromboembolism and stroke.
• Ask about current or past breast cancer and other hormone-dependent tumours.
• Check for unexplained vaginal bleeding and arrange investigations if present.
• Consider liver function tests if there is known liver disease or prolonged therapy is planned.
• Confirm allergy history, including peanut allergy relevant to some capsule excipients.

High-Risk Groups

The elderly may be more sensitive to sedative effects and to cardiovascular risk factors.

Pregnant people should only use progesterone where it is indicated and after clear clinical guidance, as pregnancy is a specific contra‑indication in some situations.

People with chronic illness such as active liver disease or previous thrombotic events require specialist review before starting micronised progesterone.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Progesterone may cause dizziness, drowsiness or fatigue in some people.

Counsel patients not to drive or operate heavy machinery until they know how the medicine affects them.

Document any advice given in pharmacy records and recommend the GP also records the counselling notes to meet NHS and MHRA expectations.

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after taking Cyclogest (micronised progesterone)?

A: There is no blanket ban on driving after taking progesterone such as cyclogest.

If you experience dizziness, drowsiness, visual disturbance or impaired concentration, do not drive or operate machinery.

Driving while impaired may breach UK road law and put you and others at risk.

Inform your prescriber or pharmacist if symptoms persist and report suspected adverse reactions via the Yellow Card scheme.

Checklist — Stop Driving If You Experience:

• Dizziness or light-headedness.
• Marked drowsiness or unexpected sleepiness.
• Blurred or disturbed vision.
• Difficulty concentrating or slowed reactions.

Usage Basics (Inn, Brands, Legal Status)

INN And Brand Names Available In The UK

People ask if Cyclogest is the same as Utrogestan or Prometrium.

The INN (International Nonproprietary Name) is progesterone, which is the active substance in cyclogest formulations.

Utrogestan is the brand commonly referenced in the UK market and appears as micronised progesterone on the packaging.

Prometrium and Progestan are other international brand names with the same active ingredient.

• INN vs Brand Names:
• INN: Progesterone — the generic active substance.
• Brand: Utrogestan — branded micronised progesterone capsules available in the UK.

• Available Dosage Strengths:
• 100 mg soft capsules/softgels.
• 200 mg soft capsules/softgels.

Legal Classification (Prescription Only In UK)

Check the MHRA patient information leaflet and NHS guidance at the point of supply.

Dosing Guide (Standard Regimens And Adjustments)

Standard Regimens (NHS-Relevant)

Soft capsules and vaginal softgels are commonly used in 100 mg and 200 mg strengths.

Adjustments For Comorbidities

Progesterone is not indicated for children; safety and efficacy are not established in paediatric patients.

Elderly patients do not usually require a specific dose reduction but increased sensitivity should be monitored.

Severe hepatic impairment is a contraindication and the medicine should not be used in that setting.

Use caution in renal impairment and monitor clinical response with limited available data.

Patients with VTE risk, migraine with aura or psychiatric history should have closer monitoring and clear documentation.

Q&A — “What If I Miss A Dose?”

Q: What should I do if I miss a dose?

A: Take the missed dose as soon as you remember unless the next scheduled dose is near.

Do not double the next dose to make up for a missed one.

If you miss multiple doses or vomit shortly after taking a dose, contact your GP or pharmacist for advice.

• Missed Dose Checklist:
• Take as soon as remembered if not near the next dose.
• Do not double up doses.
• Contact healthcare professional after repeated missed doses or vomiting.

• Signs Of Overdose:
• Nausea and vomiting.
• Excessive sedation or drowsiness.
• Withdrawal bleeding in hormone-withdrawal contexts.

Interaction Chart (Food, Drink And Medicines)

Food And Drink Interactions

No major dietary restrictions are required with micronised progesterone.

Avoid heavy alcohol consumption while taking progesterone because alcohol may worsen drowsiness and fatigue.

Caffeine has no direct significant interaction with progesterone, but increased caffeine can worsen anxiety or insomnia which may be reported as side effects.

• Keep alcohol consumption low while on progesterone.
• Monitor sleep and mood if consuming large amounts of caffeine.

Common Drug Conflicts & Pharmacovigilance

Report suspected interactions or adverse reactions to the MHRA Yellow Card scheme.

User Reports & Trends (NHS Choices, Patient.Info, Forums)

Patients frequently report a mix of benefits and side effects when using micronised progesterone.

• Common Concerns Reported By Users:
• Drowsiness and fatigue.
• Mood changes and irritability.
• Breast tenderness and mild GI upset.
• Variable efficacy for cycle regulation.
• Interest in vaginal administration to reduce systemic effects.

Anecdotal themes include improved sleep for some users and increased tiredness for others.

There is a noticeable trend towards private clinics and online pharmacies requesting micronised progesterone for cycle support and HRT.

Off-label vaginal use of oral capsules is discussed in forums and clinical practice in parts of Europe, often to boost local endometrial exposure while limiting systemic sedation.

When drafting patient-facing material, reference authoritative sources such as NHS guidance, Cochrane reviews and BMJ summaries to support claims.

Access & Purchase Options (UK Pharmacy Landscape)

High-Street And Chain Pharmacies

Major community pharmacies such as Boots, LloydsPharmacy and Superdrug routinely dispense progesterone on a valid prescription.

These pharmacies provide counselling and can contact the prescriber to clarify dose or supply issues.

Private clinic prescriptions are commonly dispensed through these chains or independent pharmacies.

Online Pharmacies And NHS E-Prescriptions

Checklist For Safe Online Purchase:

• Use an NMC-registered pharmacy website.
• Ensure a valid prescription is required and verified.
• Confirm pharmacist counselling is provided and MHRA leaflet included.

In our online pharmacy, cyclogest is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism Of Action & Pharmacology (Simplified + Clinical Terms)

Simplified Explanation

Progesterone is a naturally occurring progestogen that prepares and stabilises the endometrium.

It counteracts oestrogen-driven endometrial proliferation and supports the luteal phase or endometrial protection during HRT.

Micronised formulations improve absorption when taken orally or inserted vaginally as softgels or capsules.

Clinical Terms And Classification

• INN: Progesterone.
• Micronised Progesterone: A formulation processed to increase surface area and improve bioavailability.
• ATC Code: G03DA04 (progestogens — pregnen‑derivatives).

Diagram Suggestion: a simple schematic showing progesterone acting on the endometrium to stabilise lining and prevent oestrogen-driven hyperplasia.

Indications & Off-Label Uses (MHRA Vs Practice)

MHRA-Approved Uses (UK/EU Context)

• Secondary amenorrhoea: 400 mg orally at bedtime for 10 days to induce withdrawal bleeding.
• Endometrial protection in postmenopausal women receiving oestrogen: 200 mg orally at bedtime for 12 days of a 28-day cycle.

Off-Label Practices In NHS/Private Care

Some private clinics and practitioners use micronised progesterone off‑label for luteal support in assisted reproduction.

Vaginal administration of oral capsules is a frequently cited off‑label practice intended to increase local endometrial exposure and reduce systemic sedation for some patients.

• Approved Uses:
• Secondary amenorrhoea and endometrial protection with oestrogen.
• Off‑Label Uses:
• Luteal support in fertility treatment and vaginal administration of oral capsules.

Checklist For Documenting Off‑Label Consent:

• Explain rationale, evidence and uncertainty to the patient.
• Record the discussion and obtain written consent where appropriate.
• Ensure follow‑up arrangements are clear and documented.

Key Clinical Findings & Evidence Summary (UK/EU Focus)

Systematic reviews and randomised trials show micronised progesterone is effective for endometrial protection when used with oestrogen in HRT.

It is also effective for inducing withdrawal bleeding in secondary amenorrhoea when used in the licensed regimen.

Comparisons with synthetic progestins suggest differences in side‑effect profiles that may influence prescribing choices.

Vaginal administration can result in higher local endometrial concentrations and may be used to reduce systemic sedative effects in some patients.

Primary sources to consult include Cochrane reviews, BMJ articles and NICE guidance when forming prescribing policy.

Alternatives Matrix (NHS Prescribing Alternatives)

Comparison Table

Pros And Cons Checklist

• Pros For Micronised Progesterone:
• Natural progesterone molecule and acceptable tolerability for many users.
• Cons:
• Some formulations contain peanut oil and require allergen labelling.
• Oral bioavailability can be variable and influenced by formulation and route.

Common Questions From UK Patients (Practical Q&A)

• Is Cyclogest The Same As Utrogestan Or Prometrium?
• Yes — they contain the same active ingredient, progesterone, although excipients and brand labels differ.
• Will Progesterone Affect My Contraception?
• Short courses of progesterone for HRT or amenorrhoea are not reliable contraception; advise patients to use effective contraception if pregnancy is undesired.
• Can It Cause Weight Gain Or Mood Changes?
• Mood changes, weight fluctuation, breast tenderness and drowsiness are commonly reported side effects.

Further reading is available on NHS.uk and Patient.info for patient-friendly summaries and MHRA leaflets for regulatory detail.

Nhs Cost & Access Comparison (Table And Regional Notes)

Note: Private prices change; verify current pharmacy price lists before publication.

Registration, Pharmacovigilance & Prescribing Framework

MHRA Approval And Labelling

Progesterone products used in the UK are subject to MHRA marketing authorisation and specific labelling requirements.

Branded products such as Utrogestan are registered in European and international markets.

NHS Prescribing Framework & Safety Documentation

Prescribers should document indication, dose and regimen and confirm contraindications such as VTE risk and hepatic disease have been checked.

Advise patients about common side effects and ensure they receive or can access the MHRA patient information leaflet.

Report suspected adverse reactions via the MHRA Yellow Card scheme.

• Prescriber Checklist:
• Screen for VTE risk, breast cancer history and liver disease.
• Agree monitoring and follow‑up schedule for prolonged therapy.
• Document counselling and consider baseline investigations when appropriate.

Storage, Handling And Supply Advice (UK Household Focus)

Household And Transport Storage

Store below 25°C and protect from moisture and light.

Do not refrigerate or freeze and keep in original packaging until use.

Advise patients to keep medicines out of reach of children and avoid storing in bathrooms where humidity is high.

Return expired or unwanted medicines to the pharmacy for safe disposal.

Pharmacy Handling And Allergen Labelling

Some capsule formulations contain peanut oil; ensure allergen warnings are applied clearly to the label when relevant.

Use tamper-evident packaging for postal deliveries and include the MHRA patient leaflet with every supply.

Guidelines For Proper Use & Pharmacist Counselling (Safety First)

UK Pharmacist Counselling Style & Key Points

At the point of supply, state the indication and confirm the exact dose and regimen with the patient.

Show the patient how to take the capsule and whether it should be swallowed or inserted if the prescription indicates vaginal use.

Explain expected onset of effect and set realistic expectations for cycle regulation or endometrial protection.

Highlight common side effects such as drowsiness, mood change, breast tenderness and gastrointestinal upset.

Advise patients when to stop the medicine and seek urgent care: severe leg pain or swelling, sudden breathlessness, jaundice or severe mood change.

NHS Patient Safety Advice And Follow-Up

Recommend baseline checks where appropriate, such as VTE risk assessment and liver function in selected patients.

Schedule follow-up for those on prolonged therapy and document all advice given.

Encourage reporting of suspected adverse reactions through the Yellow Card scheme and ensure the patient has access to the MHRA patient information leaflet.

• Counselling Checklist:
• Confirm dose and regimen, show how to take or insert the capsule.
• Discuss missed-dose advice and signs of overdose.
• Explain storage and allergen considerations.
• Advise on driving and machinery if drowsiness occurs.

Patient-Facing Leaflet Template:

• What this medicine is for and how to take it.
• Common side effects and when to seek help.
• Keeping the medicine safe at home and not sharing it.
• Contact details for pharmacist or GP and Yellow Card reporting link.

Delivery Across United Kingdom